sglt2 inhibitors vs glp 1 GLP-1 Receptor Agonists and in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy | Drugs Complementary Yet Distinct Roles of

We have discussed this before, but now at the #TippingPointInObesityCare we have to take action to change it

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.

Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-oc

Appetite and craving support

This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide)

Overall, the study supports current guideline flexibility, indicating that both GLP-1RAs and SGLT2 inhibitors provide broadly similar cardiovascular protection